Some news

Dear colleagues, dear friends, dear Pneumotox users,

I transferred the chairmanship of my department to retire only partly, still joyfully practicing as a consulting hospital-based pulmonary physician in our area.

During the past years, an ever increasing but heterogenous body of literature on DIRD has emerged. This was surveyed and critically evaluated daily, as it has been for over three decades now. Since 2013, 5,400 new references were added to the bibliography section of Pneumotox through weekly updates. Large pharmacovigilance databases have shed some light on DIRD in real life. AI may emerge as a significant servant and contributor in the daily approach of this topic.

Beside surveying the literature, steering Pneumotox was a daily multifaceted challenge. As Pneumotox was built to be and stay free for all, funding was and still is a durable challenge (a “wish to donate” link is now and for the first time present on the frontpage). No least were issues related to technological advancements in computer and web science, requiring Pneumotox to be extensively overhauled to a new, more stable and secure environment. Short of being upgraded or rebuilt, websites can get vulnerable in their weak spots. As you saw, technological obsolescence shut down both Pneumotox and Cardiolox Apps. Apologies for that. The Apps have been carefully rebuilt and it is my pleasure to announce they will be back on track shortly.

Thank to a set of talented people at Akyos Communication in Dijon, Pneumotox data and files were synched, merged, transferred now secured in a safe daily backup. Pneumotox and Cardiotox websites had their graphic redesigned while staying inspired by the previous design, as a sort of soft transition. Previous features were maintained as new ones were and are being developed. Both Pneumotox and Cardiotox Apps were rejuvenated, and will be soon back at your fingertips in August, 2026.

As a safeguard, the previous version of Pneumotox is kept maintained and nested as a safe background resource, should there be any need.

I will invite distinguished colleagues to join me in an International Pneumotox Monitoring Board, to ensure the maintenance, development and progress of Pneumotox, iatrogenic science and funding.

Should you need, I encourage you to contact me, wishing Pneumotox will match your expectations in terms of quality, reliability and excellence for in the foreseable future.

As ever before, Pneumotox will stay free, ad-free and independent. I will continue answering personally any query (including rechallenge data when available) swiftly, 7/365

Thank you very much for your trust.

My warmest regards.

Philippe Camus MD